TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00705757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost
Description: Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost
Description: Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost
Description: Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
Study: NCT02914535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet(s) administered orally once daily
Study: NCT04399369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDF
Description: 38% silver diamine fluoride solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: 5% sodium fluoride varnish
Study: NCT03522818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual Trigger
Description: Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal
Description: Will use the alarm as provided by the manufacture.
Study: NCT00718094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E®
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral tablet: placebo
Study: NCT00005032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04006470

Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice

Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing potassium nitrate or arginine.

Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study: NCT01451918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: 500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
Study: NCT02899975

Intervention type: OTHER
Group type: OTHER
Intervention: Validation
Description: Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
Study: NCT04986774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue intracranial stenting
Description: Rescue Intracranial Stenting in Acute Ischemic Stroke caused by intracranial large vessel occlusion
Study: NCT04832256

Intervention type: DEVICE
Intervention: Radical-7 Pulse CO-Oximeter
Description: COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)

Intervention type: DEVICE
Intervention: Radical-7 Pulse CO-Oximeter
Description: COHb measurement monitoring from finger pulp with a non-invasive measurement device called Masimo Radical-7 Pulse co-oximeter (Masimo Corporation, Irvine, USA)
Study: NCT01218542

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy
Description: Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
Study: NCT02413957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation
Description: Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
Study: NCT01015716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-group
Description: Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-group
Description: Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
Study: NCT03289767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curved-tube
Description: Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily.
Study: NCT01038687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3309
Description: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03287076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide Injection
Description: 5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
Study: NCT03580161

Intervention type: OTHER
Intervention: 18-F FDG PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: Ga-68 PSMA PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: 68-Ga Dotatate PET/CT dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: 99mTc Pertechnetate Thyroid dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: 99mTc DMSA(III) Renal dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: 99mTc MAG3 Renal dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans

Intervention type: OTHER
Intervention: 99mTc MDP/HDP Bone dosimetry scans and measurements
Description: Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
Study: NCT00324974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole microgranules suspension
Description: Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
Study: NCT00369343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
Description: DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, daily (QD), tablet form, treatment period up to 8 weeks
Study: NCT03489343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Study: NCT04610710

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operation
Description: Operation for deep infiltrating endometriosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fertility treatment
Description: In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)
Study: NCT03143101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist trivalent (2015-2016)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist Quadrivalent (2015-2016)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist Quadrivalent (2017-2018)
Description: 0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10\^7±0.5 FFU of each vaccine strain.
Study: NCT04538469

Intervention type: OTHER
Intervention: COVID visitation restrictions
Description: Visitation to patients in hospitals in Scotland was ceased due to the COVID 19 pandemic. Slow reintroduction of visitors has been introduced, however not to the pre COVID 19 levels. This study will examine the effects of these restrictions on patients in the cardiothoracic critical care unit that do not suffer from COVID 19.
Study: NCT02773095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novartis Access
Description: Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
Study: NCT02047370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm stretching
Description: The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same therapist, patient position and duration of the technique, but using disconnected ultrasound
Study: NCT01057667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Description: 1000mg bid po, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin [Copegus]
Description: 1000mg or 1200mg po daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin [Copegus]
Description: 1000mg or 1200mg po daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180mcg sc weekly
Study: NCT03155555

Intervention type: OTHER
Intervention: Measurement of aortic and carotid Doppler peak systolic velocity variation
Description: Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
Study: NCT02412202

Intervention type: OTHER
Group type: OTHER
Intervention: Monitoring of pulmonary oedema induced by weaning from mechanical ventilation
Study: NCT02631317

Intervention type: BEHAVIORAL
Intervention: Advance hospital notification by EMS
Description: Advance hospital notification by EMS

Intervention type: BEHAVIORAL
Intervention: stroke team notification
Description: stroke team notification

Intervention type: BEHAVIORAL
Intervention: key performance indicators feedback form
Description: a key performance indicators real-time feedback form as continuing quality improvement

Intervention type: BEHAVIORAL
Intervention: standard informed consent procedures
Description: standard informed consent procedures with public poster of thrombolysis

Intervention type: BEHAVIORAL
Intervention: performance of thrombolysis at CT-room
Description: performance of thrombolysis at CT-room or emergency room
Study: NCT01409187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon
Description: 5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (Aldesleukin)
Description: 9 million IU/m\^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
Study: NCT01028404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1952
Description: Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NN1952
Description: Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
Study: NCT03340038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-ICU Specialty ward
Study: NCT02247739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03218371

Intervention type: PROCEDURE
Intervention: chandelier-assisted peripheral vitrectomy under air
Description: chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
Study: NCT04571736

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: access to the internet information platform
Description: This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.
Study: NCT04028414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Weight Bearing
Description: Patients will be instruction to weight bear as tolerated while in a boot.
Study: NCT00991289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Description: 500 mg twice daily, taken orally with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PEG)
Description: 180 micrograms via subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
Study: NCT01655719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study: NCT01051817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: infusion 10 mg/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: infusion
Study: NCT04501484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided Focused Ultrasound VIM Thalamotomy
Description: Ablation of contralateral VIM nucleus of thalamus with MRgFUS using ExAblate Neuro 4000 Device (InSightec Ltd, Tirat Carmel, Israel)
Study: NCT02571062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Study: NCT00550797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TPI ASM8
Description: Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
Study: NCT01792102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib and Dexamethasone
Description: Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m\^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m\^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16.
Study: NCT04069676

Intervention type: OTHER
Intervention: EEG
Description: EEG, ECG and EDR record during a behavioral task

Intervention type: OTHER
Intervention: EEG
Description: EEG, ECG and EDR record during a behavioral task
Study: NCT02183012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen extrudate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen extrudate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen lysinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen lysinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT02638779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Specific Blood sampling will be performed in patients and healthy volunteers
Study: NCT00237692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Behavioral intervention with Home BP Telemonitoring
Description: Nurse-administered behavior intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Medication Management with Home BP Telemonitoring
Description: Nurse administer medication management according to hypertension decision support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse Combined intervention with Home BP Telemonitoring
Description: Combination of the nurse administered tailored behavioral \& medication management
Study: NCT00289094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Rotating Platform (RP) Cruciate Retaining Knee System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Fixed Cruciate Retaining Knee System
Study: NCT03113968

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroconvulsive therapy (ECT)
Description: ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.